Clinical trial
A Study of ARQ 171 in Patients With Advanced Solid Tumors
NCT00398840 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Industry · Terminated
Key facts
| NCT number | NCT00398840 |
|---|---|
| Title | A Study of ARQ 171 in Patients With Advanced Solid Tumors |
| Official title | A Phase 1 Dose Escalation Study of ARQ 171 in Adult Patients With Advanced Solid Tumors |
| Lead sponsor | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | ARQ 171 |
| Enrollment | 14 |
| Start date | Nov 1, 2006 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Nov 14, 2006 |
| Last update posted | Mar 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: